

## DAFTAR PUSTAKA

- ADA (*American Diabetes Association*), 2022. ADA (*American Diabetes Association*). (2022). Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. *Clinical Diabetes*, 40(1), 10–38. <https://doi.org/10.2337/CD22-AS01>
- American Diabetes Association. (2022a). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. *Diabetes Care*, 45(Supplement\_1), S144–S174. <https://doi.org/10.2337/dc22-S010>
- American Diabetes Association. (2022b). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. *Diabetes Care*, 45, S144–S174. <https://doi.org/10.2337/dc22-S010>
- American Diabetes Association. (2022c). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. *Diabetes Care*, 45(Supplement\_1), S125–S143. <https://doi.org/10.2337/DC22-S009>
- Aschner, P., Gagliardino, J. J., Ilkova, H., Lavalle, F., Ramachandran, A., Mbanya, J. C., Shestakova, M., Chantelot, J.-M., & Chan, J. C. N. (2020). Correction to: Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). *Diabetologia*, 63(5), 1088–1089. <https://doi.org/10.1007/s00125-020-05118-3>
- Bader, G., Geransar, P., & Schweizer, A. (2013). Vildagliptin more effectively achieves a composite endpoint of HbA1c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. *Diabetes Research and Clinical Practice*, 100(3), e78–e81. <https://doi.org/10.1016/J.DIABRES.2013.03.011>
- Blüher, M. (2012). Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. *World Journal of Diabetes*, 3(9), 161. <https://doi.org/10.4239/wjd.v3.i9.161>
- Böhm, A. K., Schneider, U., Aberle, J., & Stargardt, T. (2021). Regimen simplification and medication adherence: Fixed-dose versus loose-dose combination therapy for type 2 diabetes. *PLOS ONE*, 16(5), e0250993. <https://doi.org/10.1371/JOURNAL.PONE.0250993>
- Brunton, S., Gough, S., Hicks, D., Weng, J., Moghissi, E., Peyrot, M., Schneider, D., Maria Schumm-Draeger, P., Tobin, C., & Barnett, A. H. (2011). A look into the future: improving diabetes care by 2015. *Current Medical Research and Opinion*, 27(SUPPL. 3), 65–72. <https://doi.org/10.1185/03007995.2011.603300>
- Chaudhary, R. K., Philip, M. J., Santhosh, A., Karoli, S. S., Bhandari, R., & Ganachari, M. S. (2021). Health economics and effectiveness analysis of generic anti-diabetic medication from jan aushadhi: An ambispective study in community pharmacy. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 15(6). <https://doi.org/10.1016/j.dsx.2021.102303>
- Cho, N., Kirigia, J., Ogurstova, K., & Reja, A. (2021). *IDF Diabetes Atlas, tenth edition*.
- Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008). Medication Compliance and Persistence: Terminology and Definitions. *Value in Health*, 11(1), 44–47. <https://doi.org/10.1111/J.1524-4733.2007.00213.X>
- De Oliveira, G. L. A., Guerra Júnior, A. A., Godman, B., & Acurcio, F. de A. (2017). Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. *Expert Review of Pharmacoeconomics & Outcomes Research*, 17(2), 109–119. <https://doi.org/10.1080/14737167.2017.1292852>
- DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., Simonson, D. C., Testa, M. A., & Weiss, R. (2015a). Type 2 diabetes mellitus. *Nature Reviews Disease Primers* 2015 1:1, 1(1), 1–22. <https://doi.org/10.1038/nrdp.2015.19>
- DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., Simonson, D. C., Testa, M. A., & Weiss, R. (2015b).

- Type 2 diabetes mellitus. *Nature Reviews Disease Primers*, 1, 15019. <https://doi.org/10.1038/nrdp.2015.19>
- ESC. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal*, 41(2), 255–323. <https://doi.org/10.1093/eurheartj/ehz486>
- European Medicines Agency. (2021). *Galvus (vildagliptin). Summaries of product characteristics*. [https://www.ema.europa.eu/en/documents/product-information/galvus-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/galvus-epar-product-information_en.pdf)
- Evans, M., Engberg, S., Faurby, M., Fernandes, J. D. D. R., Hudson, P., & Polonsky, W. (2022). Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. *Diabetes, Obesity and Metabolism*, 24(3), 377–390. <https://doi.org/10.1111/DOM.14603>
- Feldman, B. S., Cohen-Stavi, C. J., Leibowitz, M., Hoshen, M. B., & Singer, S. R. (2014). Defining the Role of Medication Adherence in Poor Glycemic Control among a General Adult Population with Diabetes. *PLoS ONE*, 9(9), 108145. <https://doi.org/10.1371/journal.pone.0108145>
- Ferrannini, E., Fonseca, V., Zinman, B., Matthews, D., Ahrén, B., Byiers, S., Shao, Q., & Dejager, S. (2009). Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes, Obesity and Metabolism*, 11(2), 157–166. <https://doi.org/10.1111/j.1463-1326.2008.00994.x>
- Fowler, M. J. (2008). Microvascular and Macrovascular Complications of Diabetes. *Clinical Diabetes*, 26(2), 77–82. <https://doi.org/10.2337/DIACLIN.26.2.77>
- García-Pérez, L.-E., 'Lvarez •, M. A., Dilla, T., Gil-Guillén, V., Orozco-Beltrán, D., García-Pérez, L.-E., 'Lvarez, M. A., & Dilla, Á. T. (2013). Adherence to Therapies in Patients with Type 2 Diabetes. *Diabetes Ther*, 4, 175–194. <https://doi.org/10.1007/s13300-013-0034-y>
- García-Pérez, L. E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013). Adherence to therapies in patients with type 2 diabetes. *Diabetes Therapy*, 4(2), 175–194. <https://doi.org/10.1007/S13300-013-0034-Y/FIGURES/1>
- GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*, 396(10258), 1204–1222. [https://doi.org/10.1016/S0140-6736\(20\)30925-9/ATTACHMENT/96EE692B-E8A2-4D2B-AB04-5A9B1490A107/MMC2E.PDF](https://doi.org/10.1016/S0140-6736(20)30925-9/ATTACHMENT/96EE692B-E8A2-4D2B-AB04-5A9B1490A107/MMC2E.PDF)
- Gomes, M. B., Rathmann, W., Charbonnel, B., Khunti, K., Kosiborod, M., Nicolucci, A., Pocock, S. J., Shestakova, M. V., Shimomura, I., Tang, F., Watada, H., Chen, H., Cid-Ruzafa, J., Fenici, P., Hammar, N., Surmont, F., & Ji, L. (2019). Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. *Diabetes Research and Clinical Practice*, 151, 20–32. <https://doi.org/10.1016/j.diabres.2019.03.024>
- Hermann, L. S., Schersten, B., Bitzén, P. O., Kjellström, T., Lindgärde, F., & Melander, A. (1994). Therapeutic Comparison of Metformin and Sulfonilurea, Alone and in Various Combinations: A double-blind controlled study. *Diabetes Care*, 17(10), 1100–1109. <https://doi.org/10.2337/DIACARE.17.10.1100>
- Hidayat, B., Ramadani, R. V., Rudijanto, A., Soewondo, P., Suastika, K., & Siu Ng, J. Y. (2022). Direct Medical Cost of Type 2 Diabetes Mellitus and Its Associated Complications in Indonesia. *Value in Health Regional Issues*, 28, 82–89. <https://doi.org/10.1016/j.vhri.2021.04.006>
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008). 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. *New England Journal of Medicine*, 359(15), 1577–1589. <https://doi.org/10.1056/nejmoa0806470>
- Keating, G. M. (2014). Vildagliptin: A review of its Use in type 2 diabetes mellitus. *Drugs*, 74(5), 587–610. <https://doi.org/10.1007/S40265-014-0199-3>

- Klarenbach, S., Cameron, C., Singh, S., & Ur, E. (2011). Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. *CMAJ*, 183(16), E1213-20. <https://doi.org/10.1503/cmaj.110178>
- Kousoulakou, H., Hatzikou, M., Baroutsou, V., & Yfantopoulos, J. (2017a). Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece. *Cost Effectiveness and Resource Allocation : C/E*, 15(1), 19. <https://doi.org/10.1186/s12962-017-0082-7>
- Kousoulakou, H., Hatzikou, M., Baroutsou, V., & Yfantopoulos, J. (2017b). Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece. *Cost Effectiveness and Resource Allocation*, 15(1). <https://doi.org/10.1186/s12962-017-0082-7>
- Kousoulakou, H., Kalogeropoulou, M., & Panitti, E. (2015). Cost-Effectiveness Analysis of Vildagliptin vs. Glimepiride as Add-On to Metformin in the Management of Type 2 Diabetes Mellitus in Greece. *Value in Health*, 18(7), A608. <https://doi.org/10.1016/J.JVAL.2015.09.2101>
- Kozma, C. M., Dickson, M., Phillips, A. L., & Meletiche, D. M. (2013a). Patient Preference and Adherence Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. *Patient Preference and Adherence*, 7–509. <https://doi.org/10.2147/PPA.S40736>
- Kozma, C. M., Dickson, M., Phillips, A. L., & Meletiche, D. M. (2013b). Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. *Patient Preference and Adherence*, 7, 509. <https://doi.org/10.2147/PPA.S40736>
- Lin, Y. S., Lin, M. T., & Cheng, S. H. (2019). Drug price, dosage and safety: Real-world evidence of oral hypoglycemic agents. *Health Policy*, 123(12), 1221–1229. <https://doi.org/10.1016/J.HEALTHPOL.2019.08.005>
- Maria Vini Pertiwi, Riza Alfian, Yunita Nita, U. A. (n.d.). *View of LAI SPECIAL EDITION: Medication adherence of diabetes mellitus patients in Indonesia: A systematic review*. Retrieved October 5, 2023, from <https://pharmacyeducation.fip.org/pharmacyeducation/article/view/1619/1297>
- Martha A. Embrey, M. S. for H. (Firm), & Edition. (2013). *MDS-3: Managing Access to Medicines and Health Technologies - Management Sciences for Health*. <https://msh.org/resources/mds-3-managing-access-to-medicines-and-health-technologies/>
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016a). Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. *Annals of Internal Medicine*, 164(11), 740–751. <https://doi.org/10.7326/M15-2650>
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016b). Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. In *Annals of Internal Medicine* (Vol. 164, Issue 11, pp. 740–751). American College of Physicians. <https://doi.org/10.7326/M15-2650>
- Mathieu, C., Barnett, A. H., Brath, H., Conget, I., De Castro, J. J., Göke, R., Márquez Rodriguez, E., Nilsson, P. M., Pagkalos, E., Penformis, A., Schaper, N. C., Wangnoo, S. K., Kothny, W., & Bader, G. (2013). Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE). *International Journal of Clinical Practice*, 67(10), 947–956. <https://doi.org/10.1111/IJCP.12252>
- Meece, J. (2014). Improving medication adherence among patients with type 2 diabetes. *Journal of Pharmacy Practice*, 27(2), 187–194. [https://doi.org/10.1177/0897190013513803/ASSET/IMAGES/LARGE/10.1177\\_089719001](https://doi.org/10.1177/0897190013513803/ASSET/IMAGES/LARGE/10.1177_089719001)



3513803-FIG3.JPEG

- Montvida, O., Shaw, J., Atherton, J. J., Stringer, F., & Paul, S. K. (2018). Long-term Trends in Anti diabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. *Diabetes Care*, 41(1), 69–78. <https://doi.org/10.2337/DC17-1414>
- Nishimura, R., Kato, H., Kisanuki, K., Oh, A., Hiroi, S., Onishi, Y., Guelfucci, F., & Shimasaki, Y. (2019). Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. *BMJ Open*, 9(3), e025806. <https://doi.org/10.1136/BMJOPEN-2018-025806>
- Oh, A., Kisanuki, K., Nishigaki, N., Shimasaki, Y., Sakaguchi, K., & Morimoto, T. (2020). Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. *Current Medical Research and Opinion*, 36(3), 387–395. <https://doi.org/10.1080/03007995.2019.1699519>
- Osterberg, L., & Blaschke, T. (2005). Adherence to Medication. *N Engl J Med*, 353.
- Ouchi, D., Giner-Soriano, M., Vilaplana-Carnerero, C., Monfa, R., Torres, F., & Morros, R. (2023). Longitudinal treatment patterns in patients recently diagnosed with type 2 diabetes mellitus in Catalonia. *Diabetes Research and Clinical Practice*, 202. <https://doi.org/10.1016/j.diabres.2023.110777>
- PERKENI. (2021a). *Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021*. PB PERKENI.
- PERKENI. (2021b). *Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021*. 46.
- Remelli, F., Ceresini, M. G., Trevisan, C., Noale, M., & Volpato, S. (2022). Prevalence and impact of polypharmacy in older patients with type 2 diabetes. *Aging Clinical and Experimental Research*, 34(9), 1969–1983. <https://doi.org/10.1007/S40520-022-02165-1/TABLES/2>
- Richter, B., Hemmingsen, B., Metzendorf, M. I., & Takwoingi, Y. (2018). Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. *The Cochrane Database of Systematic Reviews*, 10(10). <https://doi.org/10.1002/14651858.CD012661.PUB2>
- Schwartz, S. L. (2010). Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. *The American Journal of Geriatric Pharmacotherapy*, 8(5), 405–418. <https://doi.org/10.1016/J.AMJOPHARM.2010.10.003>
- Seino, Y., Kuwata, H., & Yabe, D. (2016). Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives. *Journal of Diabetes Investigation*, 7, 102–109. <https://doi.org/10.1111/JDI.12490>
- Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P. H., Handelsman, Y., Insel, R. A., Mathieu, C., McElvaine, A. T., Palmer, J. P., Pugliese, A., Schatz, D. A., Sosenko, J. M., Wilding, J. P. H., & Ratner, R. E. (2017). Differentiation of diabetes by pathophysiology, natural history, and prognosis. In *Diabetes* (Vol. 66, Issue 2, pp. 241–255). American Diabetes Association. <https://doi.org/10.2337/db16-0806>
- Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corliano, F., Paolo Fra, G., Bartoli, E., & Derosa, G. (2015). Sulfonylureas and their use in clinical practice. In *Archives of Medical Science* (Vol. 11, Issue 4, pp. 840–848). Termedia Publishing. <https://doi.org/10.5114/aoms.2015.53304>
- Stratton, I. M., Adler, A. I., Neil, H. A. W., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. *British Medical Journal*, 321(7258), 405–412. <https://doi.org/10.1136/bmj.321.7258.405>
- Teck, J. (2022). Diabetes-Associated Comorbidities. *Primary Care: Clinics in Office Practice*, 49(2), 275–286. <https://doi.org/10.1016/j.pop.2021.11.004>
- Thornberry, N. A., & Gallwitz, B. (2009). Mechanism of action of inhibitors of dipeptidyl-peptidase-

- 4 (DPP-4). *Best Pract Res Clin Endocrinol Metab*, 23(4), 479–486. <https://doi.org/10.1016/j.beem.2009.03.004>
- Tjokroprawiro, A., Murtiwi, S., & Tjandrawinata, R. R. (2016). DLBS3233, a combined bioactive fraction of *Cinnamomum burmanii* and *Lagerstroemia speciosa*, in type-2 diabetes mellitus patients inadequately controlled by metformin and other oral antidiabetic agents. *Journal of Complementary and Integrative Medicine*, 13(4), 413–420. <https://doi.org/10.1515/JCIM-2016-0031/MACHINEREADABLECITATION/RIS>
- Van Gaal Michel Hermans Evis Daci Kris Denhaerynck Lut De Meester Karen MacDonald Ivo Abraham Stefaan Vancayzeele Michael Maris, L. P. (2019). Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study. *Diabetes Therapy*, 10. <https://doi.org/10.6084/m9.figshare.7831796>
- Viriato, D., Calado, F., Gruenberger, J. B., Ong, S. H., Carvalho, D., Silva-Nunes, J., Johal, S., & Viana, R. (2014a). Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. *J Med Econ.*, 17(7), 499–507. <https://doi.org/10.3111/13696998.2014.912986>
- Viriato, D., Calado, F., Gruenberger, J. B., Ong, S. H., Carvalho, D., Silva-Nunes, J., Johal, S., & Viana, R. (2014b). Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: A Portuguese healthcare system perspective. *Journal of Medical Economics*, 17(7), 499–507. <https://doi.org/10.3111/13696998.2014.912986>
- World Health Organization. (n.d.). *Diabetes*. Retrieved June 8, 2022, from <https://www.who.int/news-room/fact-sheets/detail/diabetes>
- World Health Organization. (2018). *Methods to analyse medicine utilization and expenditure to support pharmaceutical policy implementation*. World Health Organization.
- Ziegler, D., Bönhof, G. J., Strom, A., Straßburger, K., Karusheva, Y., Szendroedi, J., & Roden, M. (2021). Progression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years. *Brain: A Journal of Neurology*, 144(10), 3251–3263. <https://doi.org/10.1093/BRAIN/AWAB330>